Objectives: Overweight negatively affects pediatric respiratory function. In this study, we evaluate if overweight is associated with more severe bronchiolitis in hospitalized infants.

Methods: This retrospective cohort study analyzed infants aged 30 to 365 days hospitalized for bronchiolitis from September 2019 to April 2020. Exclusion criteria included known risk factors for severe bronchiolitis, asthma treatment, or bacterial pneumonia. Weight-for-length z-score was categorized per the World Health Organization's growth assessments as overweight (z-score >2), underweight (z-score <-2), and standard weight (between -2 and ≤2). Primary outcomes included respiratory support, ICU stay, and local bronchiolitis score. Secondary outcomes included supplemental interventions.

Results: After exclusion criteria, 385 of 644 infants were categorized as overweight (n = 24), standard (n = 335), or underweight (n = 26). There were differences in need for respiratory support (overweight, 100%; standard weight, 81.8%; underweight, 76.9%; P = .03), highest support of high-flow nasal cannula (overweight, 75%; standard weight, 48%; underweight, 42%; P = .03), admission to ICU (overweight, 54.2%; standard weight, 21.5%; underweight, 34.7%; P < .001), and median bronchiolitis score (overweight, 8 [interquartile range 5-10]; standard weight, 4 [3-7]; underweight, 4 [3-7]; P = .01). Findings remained significant after age adjustments. Additionally, overweight experienced higher frequency of certain treatments.

Conclusions: This study suggests overweight is associated with more severe bronchiolitis in hospitalized infants supported by increased respiratory support level, bronchiolitis scores, and interventions. Higher need for ICU admission may be related to high-flow nasal cannula limitations on the acute care floor.

Download full-text PDF

Source
http://dx.doi.org/10.1542/hpeds.2022-006746DOI Listing

Publication Analysis

Top Keywords

hospitalized bronchiolitis
8
associated severe
8
severe bronchiolitis
8
overweight
4
overweight infants
4
infants hospitalized
4
bronchiolitis
4
bronchiolitis associated
4
severe disease
4
disease objectives
4

Similar Publications

Objective: The Sedation and Weaning in Children (SANDWICH) trial of a sedation weaning and ventilator liberation bundle had a primary outcome of time to successful extubation, and showed significant but small difference. We explored the impact of the intervention on infants with bronchiolitis.

Design: Post hoc subgroup analysis of a cluster-randomized trial, 2018 to 2019 (ISRCTN16998143).

View Article and Find Full Text PDF

Purpose: There is limited evidence to guide the treatment of enteral nutrition (EN) for children with bronchiolitis who receive biphasic positive airway pressure (BiPAP) support.

Methods: This quality improvement project included patients with bronchiolitis who were supported by BiPAP ventilation. An algorithm to increase EN treatment in those patients was created by stakeholders.

View Article and Find Full Text PDF

Mycoplasma pneumoniae (MP) is one of the pathogens that cause community-acquired pneumonia in children. Atopic diseases are also common in children. However, the impact of atopy on Mycoplasma pneumoniae pneumonia (MPP) in children is still unclear.

View Article and Find Full Text PDF

Identifying High-Risk Patients for Paediatric Unplanned Readmissions: Insights From a Western Sydney Hospital.

J Paediatr Child Health

January 2025

Department of Paediatrics, Nepean Hospital, Nepean Blue Mountains Local Health District, Penrith, Australia.

Aim: To identify factors and diagnoses associated with unplanned readmission of paediatric patients to a Western Sydney metropolitan hospital.

Method: A retrospective cross-sectional study on paediatric patients admitted to a non-tertiary hospital in Western Sydney from January 2017 to December 2022. Multivariate modelling was used to determine demographic factors and diagnoses associated with unplanned readmission.

View Article and Find Full Text PDF

Background: In Catalonia, infants <6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyze nirsevimab's effectiveness in hospital-related outcomes of the seasonal cohort (born during the RSV epidemic from October to January 2024) and compared them with the catch-up cohort (born from April to September 2023).

Methods: Retrospective cohort study of all infants born between October 1, 2023, and January 21, 2024, according to their immunization with nirsevimab (immunized and nonimmunized).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!